The Tiny $1.3b High Yield ETF That Retirees Should Consider Now | DHS

Photo of Michael Williams
By Michael Williams Published

Quick Read

  • DHS returned 17.6% over the past year but its monthly distributions declined 8.5% from 2023 to 2025.

  • AbbVie pays $6.56 in dividends against only $1.33 in earnings per share due to Humira patent loss.

  • The fund holds 9% combined exposure to tobacco companies including Altria at 7.06% yield.

  • The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

The WisdomTree U.S. High Dividend Fund (NYSEARCA:DHS) offers retirees monthly income and capital appreciation. With $1.3 billion in assets and a 3.46% yield, this ETF holds diversified high-dividend U.S. equities. The fund’s defensive tilt (41% in consumer staples, healthcare, and utilities) provides stability, while its 0.38% expense ratio keeps costs low.

DHS delivers monthly distributions, attractive for retirees managing cash flow. Over the past year, the fund combined its 3.46% yield with 14.15% price appreciation for approximately 17.6% total return.

Dividend Safety of Top Holdings

DHS’s dividend sustainability depends on its top holdings. The three largest positions (AbbVie, Exxon Mobil, and Altria) account for 14.5% of the portfolio.

AbbVie (NYSE:ABBV | ABBV Price Prediction) (4.92% of portfolio) presents the biggest concern. The pharmaceutical giant pays a $6.56 annual dividend against just $1.33 in diluted earnings per share—a 493% earnings payout ratio. This stems from an 88.7% year-over-year earnings decline in Q3 2025, reflecting the “Humira cliff” as the blockbuster drug loses patent exclusivity. However, its operating cash flow payout ratio of 59% is more sustainable, and its forward P/E of 16x suggests analysts expect earnings recovery. With a 35.5% operating margin and $403.8 billion market cap, AbbVie can maintain its dividend near-term, but growth is unlikely until new products compensate for Humira’s decline.

Exxon Mobil (NYSE:XOM) (4.91% of portfolio) demonstrates exceptional dividend safety. The company’s $3.96 annual dividend represents just 58% of its $6.88 EPS – and only 30% of its $55 billion operating cash flow. Exxon generated $33.7 billion in net income during 2024 while paying $16.7 billion in dividends, leaving substantial room for growth. The company’s fortress balance sheet makes its 3.27% yield highly reliable, even during commodity price volatility.

Altria (NYSE:MO) (4.67% of portfolio) offers the highest yield at 7.06% but carries elevated risk. The tobacco company’s 78% payout ratio based on both earnings and operating cash flow leaves minimal cushion. While Altria’s 44% profit margin and 62.8% operating margin provide support, declining cigarette volumes and regulatory headwinds threaten long-term sustainability. The company’s negative book value of -$1.576 reflects heavy debt from buybacks. For ESG-conscious retirees, Altria’s 9% combined tobacco exposure (including Philip Morris (NYSE:PM) at 4.27%) may be problematic.

Total Return Analysis

DHS delivered 14.15% price appreciation over the past year, combined with approximately 3.2% in dividend income for 17.4% total return—roughly matching the S&P 500. However, over 10 years, DHS gained 148% versus the S&P 500’s 230% – a trade-off investors accept for lower volatility and consistent income.

The fund’s dividend payments declined from $3.53 in 2023 to $3.38 in 2024 and $3.23 in 2025, an 8.5% decrease over two years. Monthly distributions fluctuate between $0.12 and $0.58, which may complicate budgeting.

Consider SCHD as an Alternative

For retirees seeking dividend growth with lower concentration risk, the Schwab U.S. Dividend Equity ETF (NYSE:SCHD) merits consideration. SCHD tracks the Dow Jones U.S. Dividend 100 Index, screening for dividend quality, consistency, and growth rather than just high yield. The fund offers a 3.8% yield with quarterly payments and has delivered 10-year annualized returns of 10.38%. SCHD’s focus on dividend aristocrats and quality factors may provide better downside protection during market stress.

DHS remains suitable for retirees prioritizing monthly income and accepting higher concentration in mature, high-yielding sectors. However, investors should monitor AbbVie’s earnings recovery and remain comfortable with significant tobacco exposure.

Photo of Michael Williams
About the Author Michael Williams →

I am a long time investor and student of business, and believe finding good companies that can become great investments is the best game on earth. After 20 years of writing and researching the public markets it is clear that individuals have never had more tools and information to take control of their financial lives. From ETFs and $0 commissions to cryptos and prediction markets there has never been a greater democratization of access to investing. 

I write to help people understand the investments available to them so they can make the best choice for their portfolio, whether they're starting out or looking for income in retirement. 

Continue Reading

Top Gaining Stocks

ON Vol: 1,467,434
TXN Vol: 720,327
3M
MMM Vol: 712,296
FSLR Vol: 141,548
MU Vol: 9,720,140

Top Losing Stocks

CTRA Vol: 73,319,495
GDDY Vol: 117,475
MRNA Vol: 880,391
SBAC Vol: 141,047
CEG Vol: 395,846